Page 57 - GPD-4-2

Gene & Protein in Disease Orexin in depression

86. Ripley B, Overeem S, Fujiki N, et al. CSF hypocretin/orexin doi: 10.1002/erv.2484
levels in narcolepsy and other neurological conditions. 97. Roveta F, Marcinno A, Cremascoli R, et al. Increased orexin
Neurology. 2001;57(12):2253-2258.
a concentrations in cerebrospinal fluid of patients with
doi: 10.1212/wnl.57.12.2253 behavioural variant frontotemporal dementia. Neurol Sci.
2022;43(1):313-317.
87. Nishino S, Okuro M, Kotorii N, et al. Hypocretin/orexin
and narcolepsy: New basic and clinical insights. Acta Physiol doi: 10.1007/s10072-021-05250-x
(Oxf). 2010;198(3):209-222. 98. Li H, Lu J, Li S, et al. Increased hypocretin (orexin)
doi: 10.1111/j.1748-1716.2009.02012.x plasma level in depression, bipolar disorder patients. Front
Psychiatry. 2021;12:676336.
88. Salomon RM, Ripley B, Kennedy JS, et al. Diurnal variation of
cerebrospinal fluid hypocretin-1 (orexin-A) levels in control doi: 10.3389/fpsyt.2021.676336
and depressed subjects. Biol Psychiatry. 2003;54(2):96-104. 99. Tsuchimine S, Hattori K, Ota M, et al. Reduced plasma
doi: 10.1016/s0006-3223(02)01740-7 orexin-a levels in patients with bipolar disorder.
Neuropsychiatr Dis Treat. 2019;15:2221-2230.
89. Luo X, Zhu D, Li J, et al. Selection of the optimal dose
of sertraline for depression: A dose-response meta- doi: 10.2147/NDT.S209023
analysis of randomized controlled trials. Psychiatry Res. 100. Yu H, Ni P, Zhao L, et al. Decreased plasma neuropeptides
2023;327:115391. in first-episode schizophrenia, bipolar disorder, major
doi: 10.1016/j.psychres.2023.115391 depressive disorder: Associations with clinical symptoms
and cognitive function. Front Psychiatry. 2023;14:1180720.
90. MacQueen G, Born L, Steiner M. The selective serotonin
reuptake inhibitor sertraline: Its profile and use in psychiatric doi: 10.3389/fpsyt.2023.1180720
disorders. CNS Drug Rev. 2001;7(1):1-24. 101. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell
doi: 10.1111/j.1527-3458.2001.tb00188.x loss in Parkinson’s disease. Brain. 2007;130(Pt 6):1586-1595.
91. Xiao X, Yeghiazaryan G, Hess S, et al. Orexin receptors doi: 10.1093/brain/awm097
1 and 2 in serotonergic neurons differentially regulate 102. Alo R, Avolio E, Mele M, et al. Role of leptin and orexin-a
peripheral glucose metabolism in obesity. Nat Commun. within the suprachiasmatic nucleus on anxiety-like behaviors
2021;12(1):5249. in hamsters. Mol Neurobiol. 2017;54(4):2674-2684.
doi: 10.1038/s41467-021-25380-2 doi: 10.1007/s12035-016-9847-9
92. Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, 103. Wang C, Wang Q, Ji B, et al. The orexin/receptor system:
Learned-Coughlin S. A review of the neuropharmacology Molecular mechanism and therapeutic potential for
of bupropion, a dual norepinephrine and dopamine neurological diseases. Front Mol Neurosci. 2018;11:220.
reuptake inhibitor. Prim Care Companion J Clin Psychiatry.
2004;6(4):159-166. doi: 10.3389/fnmol.2018.00220
doi: 10.4088/pcc.v06n0403 104. Suchting R, Yoon JH, Miguel GGS, et al. Preliminary
examination of the orexin system on relapse-related factors
93. Scammell TE, Arrigoni E, Lipton JO. Neural circuitry of in cocaine use disorder. Brain Res. 2020;1731:146359.
wakefulness and sleep. Neuron. 2017;93(4):747-765.
doi: 10.1016/j.brainres.2019.146359
doi: 10.1016/j.neuron.2017.01.014
105. Mediavilla C. Bidirectional gut-brain communication:
94. Gotter AL, Webber AL, Coleman PJ, Renger JJ, Winrow CJ. A role for orexin-A. Neurochem Int. 2020;141:104882.
International union of basic and clinical pharmacology.
LXXXVI. Orexin receptor function, nomenclature and doi: 10.1016/j.neuint.2020.104882
pharmacology. Pharmacol Rev. 2012;64(3):389-420. 106. Fagan H, Jones E, Baldwin DS. Orexin receptor antagonists
doi: 10.1124/pr.111.005546 in the treatment of depression: A leading article summarising
pre-clinical and clinical studies. CNS Drugs. 2023;37(1):1-12.
95. Wang JY, Han F, Dong SX, et al. Cerebrospinal fluid orexin
a levels and autonomic function in kleine-levin syndrome. doi: 10.1007/s40263-022-00974-6
Sleep. 2016;39(4):855-860. 107. Uğurlu M. Orexin receptor antagonists as adjunct drugs for
doi: 10.5665/sleep.5642 the treatment of depression: A mini meta-analysis. Noro
Psikiyatr Ars. 2024;61(1):77-84.
96. Sauchelli S, Jimenez-Murcia S, Fernandez-Garcia JC,
et al. Interaction between orexin-a and sleep quality in doi: 10.29399/npa.28383
females in extreme weight conditions. Eur Eat Disord Rev. 108. Han Y, Yuan K, Zheng Y, Lu L. Orexin receptor antagonists
2016;24(6):510-517. as emerging treatments for psychiatric disorders. Neurosci

Volume 4 Issue 2 (2025) 21 doi: 10.36922/gpd.4210